The National Pharmaceutical Pricing Authority (NPPA) has slapped a Rs 300-crore
fine on Swiss multinational Novartis for
overcharging consumers on sale of Voveran, its best-selling painkiller medicine,
according to a Business Standard report.
Voveran is based on diclofenac, a component that is under the government's direct price control, adds the report. According to IMS Health annual data, Voveran, with annual sales of about Rs 225 crore, was among the top 10 brands in the domestic drug retail market as of April this year
Voveran is based on diclofenac, a component that is under the government's direct price control, adds the report. According to IMS Health annual data, Voveran, with annual sales of about Rs 225 crore, was among the top 10 brands in the domestic drug retail market as of April this year
No comments:
Post a Comment